期刊文献+

UGT1A9 C-2152T和UGT2B7 G211T突变在中国汉族人群中的分布 被引量:9

Distribution of UGT1A9 C-2152T and UGT2B7 G211T mutants in Chinese Han population
下载PDF
导出
摘要 目的:建立Touch-down PCR/RFLP的方法检测UGT1A9C-2152T突变,建立PCR/RFLP的方法检测UGT2B7G211T突变,确定其在中国汉族人群中的突变频率。方法:采用Touch-down PCR/RFLP方法,对100名无亲缘关系的汉族男性志愿者进行UGT1A9C-2152T的基因分型。采用PCR/RFLP方法,对363名无亲缘关系的汉族志愿者(其中男性263名、女性100名)进行UGT2B7 G211T的基因分型。结果:在100名中国汉族男性受试者中,末发现UGT1A9C-2152T的突变,与亚洲人通过测序报道的结果基本一致。在363名汉族受试者中,UGT2B7G211T突变发生频率为0.158,与日本人通过测序报道的结果基本一致。中国男性和女性的等位基因频率分别为0.128和0.110,男性的突变频率比女性高(χ2=6.784,P=0.034)。结论:用PCR/RFLP的方法对UGT2B7 G211T突变分型的方法简便、快速、重复性好,可用于大样本人群的基因检测。UGT2B7G211T突变在中国汉族人中发生频率较高。 AIM: Detection of UGT2B7 G211T and UGT1A9 C-2152T variant alleles, and knowledge about their allelic frequency in a Chinese population. METHODS: To determine the allelic frequency of the UGT1A9 C-2152T in a group of 100 Chinese male subjects by using of touch-down polymerase chain reaction-restriction fragment length polymorphism (Touch-down PCR/RFLP) assays. To determine the allelic frequency of the UGT2B7 G211T mutant in a group of 363 Chinese subjects by using of polymerase chain reaction-restriction fragment length polymorphism (PCR/RFLP) assays. RESULTS: The frequency of the UGT1A9 C-2152T mutant allele was rare in a Chinese population which was similar to that of Asian people. In a group of 363 tmrelated individuals, the frequency of the UGT2B7 G211T mutant in Chinese population was 0. 158, which was similar to that of Japanese. The allelic frequency in Chinese male was 0. 128, which was statistically higher than that of Chinese female 0.110. CONCLUSION: We have found a PCR-RFLP assay for genotyping UGT2B7 G211T mutant. This straightforward and prompt PCR-RFLP assay has a good reproducibility, and therefore can be used to genotype for the UGT2B7 G211T polymorphism in a large population samples. The frequency of the UGT2B7 G211T mutant allele is high in a Chinese population.
出处 《中国临床药理学与治疗学》 CAS CSCD 2007年第4期460-464,共5页 Chinese Journal of Clinical Pharmacology and Therapeutics
关键词 UGT1A9 UGT2B7 突变 基因型 中国 汉族人群 UGT1A9 UGT2B7 mutant genotype
  • 相关文献

参考文献13

  • 1Gong QH,Cho JW,Huang T,et al.Thirteen UDP glucuronosyltransferase genes are encoded at the human UGT1 gene complex locus[J].Pharmacogenetics,2001;11:357-368.
  • 2Albert C,Vallee M,Beaudry G,et al.The monkey and human uridine diphosphate glucuronosyltransferase UGT1A9,expressed in steroid target tissues,are estrogen-conjugating enzymes[J].Endocrinology,1999,140:3292-3302.
  • 3Riedy M,Wang JY,Miller AP,et al.Genomic organization of the UGT2b gene cluster on human chromosome 4q13[J].Pharmacogenetics,2000;10:251-260.
  • 4Ritter JK,Sheen YY,Owens IS.Cloning and expression of human liver UDP-glucuronosyltransferase in COS-1 cells.3,4-Catechol estrogens and estriol as primary substrates[J].J Biol Chem,1990;265:7900-7906.
  • 5Coffman BL,Rios GR,King CD,et al.Human UGT2B7 catalyzes morphine[J].Drug Metab Disposl,1997;25:1-4.
  • 6Takeshi H,Ichiro I,Hiroshe T,et al.Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy[J].Drug Metab Dispos,2003;31:677-680.
  • 7Coffman BL,Kearney WR,Green MD,et al.Analysis of opioid binding to UDP-glucurosyltransferase 2B7 fusion proteins using nuclear magnetic resonance spectroscopy[J].Mol Pharmacol,2001;59:1464-1469.
  • 8Sambrook J.Molecular cloning(A laboratory Manual)[M].2nd edition.Cold Spring Harbor Labo.
  • 9Hugo Girarda,Michael H.Courtb,et al.Identification of common polymorphisms in the promoter of the UGT1A9 gene:evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver[J].Pharmacogenetics,2004;14:501-515.
  • 10Strassburg CP,Manns MP,Tukey RH.Differential down-regulation of the UDP-glucuronosyltransferase 1A locus is an early event in human liver and biliary cancer[J].Cancer Res,1997;57:2979-2985.

同被引文献97

  • 1彭向前,张鉴,李军.口服降糖药的研究进展及临床评价[J].中国医院用药评价与分析,2005,5(1):19-21. 被引量:25
  • 2欧江荣,谭兰,孙妍萍.丙戊酸药物浓度与CYP2B6基因多态性的相关性研究[J].中国临床神经科学,2007,15(4):378-381. 被引量:7
  • 3Stefan,h.,Feuerstein,TJ.Novel anticonvulsant drugs[J].Pharmacology & Therapeutics,2007,113:165-183.
  • 4Rowland A,Elliot DJ,Williams JA,et al.In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction[J].Drug Metab Dispos,2006,34:1055-1062.
  • 5Wootton R,Soul-Lawton J,Rolan PE,et al.Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers[J].Br J Clin Pharmacol,1997,43:23-27.
  • 6Hussein Z,Posner J.Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy:retrospective analysis of routine monitoring data[J].Br J Clin Pharmacol,1997,43:457-465.
  • 7Chan V,Morris RG,Ilett KF,et al.Population Pharma-cokinetics of Lamotrigine[J].Therapeutic Drug Monitoring,2001,23(6):630-635.
  • 8Chen C.Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children[J].Br J Clin Pharmacol,2000,50:135-145.
  • 9Vander WJ.Maintenance dose requirement for phenytoin is lowered in genetically impaired drug metabolism independent of concommitant use of other antiepileptics[J].Ned Tijdschr Geneeskd,2001,145:312-315.
  • 10Perucca E.Pharmacological and therapeutic properties of valproate,a summary after 35 years of clinical experience[J].CNS Drugs,2002,16:695-714.

引证文献9

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部